2002 Chrysler Pt Cruiser Limited Edition on 2040-cars

Auto blog

EIB ups financing for Fiat Chrysler's electric vehicles to $949 million

MILAN — The European Investment Bank (EIB) has increased to almost 800 million euros ($949 million) its funding to Fiat Chrysler Automobiles (FCA) to support production of electric and hybrid vehicles, they said in a joint statement. Investments to manufacture battery electric vehicles and plug-in hybrid electric vehicles will be mainly directed at FCA plants located in southern Italy, supporting employment and compliance with the strictest environmental criteria. To improve capacity utilization at FCA's Italian plants, the group has announced a 5 billion euro investment plan for the country through 2021 which envisages the launch of new electric and hybrid models. EIB and FCA had sealed 300 million euros in financing before the summer to fund investments for plug-in hybrid electric vehicle production lines at plants in Melfi, in the southern Basilicata region, and battery electric vehicles at Fiat's historic Turin plant of Mirafiori over the 2019-2021 period. FCA has now finalized a 485 million euro deal with EIB to support both an innovative line of plug-in hybrid electric vehicles at the Pomigliano plant in the southern Campania region as well as R&D activities at FCA laboratories in Turin. The EIB credit line covers 75% of the total value of FCA's investment in the project for the 2020-2023 period. Earnings/Financials Green Plants/Manufacturing Chrysler Fiat

Junkyard Gem: 1989 Chrysler TC by Maserati

Lee Iacocca's friendship with Alejandro de Tomaso went way back, and it led to the Ford-powered De Tomaso Pantera being born in 1971 (when Iacocca was running Ford). After Iacocca moved over to head Chrysler in 1978, he began working with de Tomaso (who owned Maserati by that point) to develop a sports coupe based on the Chrysler-salvation K-Car platform. It took quite a while, but eventually that car became reality: the Chrysler TC by Maserati (officially known as Chrysler's TC by Maserati). Some 7,300 were built through 1991, and I've found one of them in a Denver-area car graveyard. I've managed to document four of these cars in their final parking spots prior to this one, in wrecking yards in Colorado, California, and Wisconsin. The Chrysler's TC by Maserati does have a devoted following, but they can't save 'em all. The TC really was assembled by Maserati in Italy, but the underlying chassis was taken from the Dodge Daytona. The body bore a strong resemblance to that of the Chrysler LeBaron GTC, which was unfortunate considering the price difference between the two cars: the MSRP on the 1989 TC was $33,000, while the LeBaron GTC cost $17,435 (that's about $80,880 and $42,730 in 2022 dollars). The TC had three different engines driving the front wheels over its short lifetime: two varieties of turbocharged Chrysler 2.2 four-cylinder (one with 160 horsepower and one with a Cosworth cylinder head with 200 horsepower) and that good old workhorse of a Mitsubishi V6: the 6G72, with 141 horses. This car has the 160hp 2.2. The Cosworth-headed cars (500 were built) got a five-speed manual transmission, but the other 6,800 TCs got a Chrysler slushbox of either three or four speeds (this one is a three-speed). There was a lot of snobbish disapproval of the TC by the automotive press, but just look at that interior! Even the most over-the-top LeBaron never got this level of swank inside.  Every time I write about one of these cars, I hear that the factory hardtop roof is worth fantastic money… but four out of the five examples I've found in junkyards had the hardtop, and I think every single one went to the crusher with its car. How many miles? Not many! Maybe the speedometer cable broke in 1995. The radio and HVAC controls are straight LeBaron, but the wood and leather are the real thing.

Fiat Chrysler says it did not know about Marchionne's illness

ZURICH/MILAN — Fiat Chrysler said it knew nothing about the medical condition of Sergio Marchionne after a Swiss hospital said on Thursday it had been treating the deceased chief executive for more than a year. "Due to medical privacy, the company had no knowledge of the facts relating to Mr. Marchionne's health," a Fiat Chrysler spokesman said. Questions have been raised about how long Marchionne, who died on Wednesday, was ill and how much the company knew before it made the situation public. Marchionne rescued Fiat and Chrysler from bankruptcy after taking the wheel of the Italian carmaker in 2004 and he multiplied Fiat's value 11 times through 14 years of canny dealmaking. He was due to step down at FCA in April next year. "The company was made aware that Mr. Marchionne had undergone shoulder surgery and released a statement about this," the spokesperson said. "On Friday, July 20, the company was made aware with no detail by Mr. Marchionne's family of the serious deterioration in Mr. Marchionne's condition and that as a result he would be unable to return to work. The company promptly took and announced the appropriate action the following day." Asked whether the scope of the statement included the board and the chairman, the company declined to comment. In emailed comments, Marchionne's family confirmed the companies had not been aware of his health conditions. "At the end of last week FCA was made aware Sergio Marchionne would no longer be able to return to work without mentioning any further details," the family said. The announcement of the death of Marchionne, 66, one of the auto industry's most tenacious and respected CEOs, drew tributes from rivals and tears from his closest colleagues on Wednesday. University Hospital Zurich said earlier on Thursday Marchionne had been treated for a serious illness for more than a year before his death. Marchionne had fallen gravely ill after what the company had described as shoulder surgery at a Zurich hospital. He was replaced as chief executive last weekend after Fiat Chrysler (FCA) said his condition had worsened. "Mr. Sergio Marchionne was a patient at USZ. Due to serious illness, he had been the recipient of recurring treatment for more than a year," the hospital said in a statement. "Although all the options offered by cutting-edge medicine were utilized, Mr.